MedTrace Logo

Haploid Allogeneic Transplant Using the CliniMACS System

NCT00185679 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2015-03-09

Study results available
· View outcomes & findings →

Summary

To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.

Conditions

  • Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors
  • Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase
  • Myelodysplastic Syndrome (MDS) - High and Intermediate Risk
  • Non-Hodgkin's Lymphoma (NHL)
  • Chronic Lymphocytic Leukemia (CLL) - Refractory

Interventions

DEVICE

CliniMACS System

The CliniMACS System is a cell selection device consisting of the following components: 1. Computer-controlled instrument; 2. Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix) 3. Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle) 4. Wash buffer

Sponsors & Collaborators

  • Ginna Laport

    lead OTHER

Principal Investigators

  • Ginna G Laport, MD · Stanford Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-30
Primary Completion
2009-10-31
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00185679 on ClinicalTrials.gov